TABLE 3

Multivariate regression results in matched cohorta

Covariate and treatment groupAdjusted odds ratioCIP value
TZP-VANReferenceReferenceReference
FEP-VAN2.181.64–2.94<0.001
VAN dose (mg/day)
    <1,0000.530.16–1.390.3
    1,000–1,4991.010.72–1.420.9
    1,500–1,999ReferenceReferenceReference
    2,000–2,4991.080.79–1.480.6
    2,500–2,9991.160.81–1.650.4
    3,000–3,9991.611.11–2.320.01
    ≥4,0001.30.5–3.050.6
Duration of VAN therapy of ≥7 days1.471.14–1.890.003
Acyclovir exposure2.221.17–4.070.01
Amphotericin B exposure2.251.14–4.410.02
Loop diuretic exposure2.782.22–3.50<0.001
Calcineurin inhibitor exposure1.620.85–2.980.1
Dehydration exposure1.811.18–2.720.005
  • a FEP, cefepime; TZP, piperacillin-tazobactam; VAN, vancomycin.